Hip and vertebral osteoporotic fractures are associated with considerable immediate and long-term increased risk of death
The fracture event itself is responsible for part of this increased mortality risk; however, other factors such as age, sex, comorbidities and poor prefracture health status are also involved
The majority of incident osteoporotic fractures are nonhip, nonvertebral fractures
Evidence of mortality risk in nonhip, nonvertebral fractures is lacking, but evidence of an increased mortality risk with some fractures, such as those in the pelvis and humerus, does exist
Medical treatment with bisphosphonates has been associated with a decreased risk of mortality in patients with osteoporotic fractures in some observational studies and in one randomized controlled trial
Decreased cardiovascular-related mortality could be one of the potential mechanisms for the decreased risk of mortality with bisphosphonate therapy; however, further studies are required to clarify this point
The rates of incident osteoporotic fractures seem to be stabilizing; however, fragility fractures are still associated with considerable disability, costs and an increased risk of mortality, which is particularly the case for fractures of the hip and vertebra. Mortality is usually highest during the first year after fracture; however, a notably increased mortality risk might persist for several years after the event. In addition to its efficacy in the prevention of new and recurrent osteoporotic fractures, medical treatment has been associated with improved survival after osteoporotic fractures. Observational studies and randomized controlled clinical trials have reported increased survival in patients with a fracture who are treated with bisphosphonates. Rates of medical treatment in patients with osteoporosis remain low, and although the rationale for the putative increase in survival is unclear, this emerging evidence might help further justify the use of medical treatment after fracture. However, further work is needed before medical therapy for mortality prevention in patients with osteoporotic fractures is accepted.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Browner, W. S., Seeley, D. G., Vogt, T. M. & Cummings, S. R. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 338, 355–358 (1991).
Johansson, C., Black, D., Johnell, O., Oden, A. & Mellstrom, D. Bone mineral density is a predictor of survival. Calcif. Tissue Int. 63, 190–196 (1998).
Kado, D. M., Browner, W. S., Blackwell, T., Gore, R. & Cummings, S. R. Rate of bone loss is associated with mortality in older women: a prospective study. J. Bone Miner. Res. 15, 1974–1980 (2000).
Qu, X. et al. Bone mineral density and all-cause, cardiovascular and stroke mortality: a meta-analysis of prospective cohort studies. Int. J. Cardiol. 166, 385–393 (2013).
Burge, R. et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J. Bone Miner. Res. 22, 465–475 (2007).
Abrahamsen, B., van Staa, T., Ariely, R., Olson, M. & Cooper, C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos. Int. 20, 1633–1650 (2009).
Huntjens, K. M. et al. Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Osteoporos. Int. 21, 2075–2082 (2010).
Johnell, O. et al. Mortality after osteoporotic fractures. Osteoporos. Int. 15, 38–42 (2004).
Alegre-Lopez, J., Cordero-Guevara, J., Alonso-Valdivielso, J. L. & Fernandez-Melon, J. Factors associated with mortality and functional disability after hip fracture: an inception cohort study. Osteoporos. Int. 16, 729–736 (2005).
Empana, J. P., Dargent-Molina, P. & Breart, G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J. Am. Geriatr. Soc. 52, 685–690 (2004).
LeBlanc, E. S. et al. Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch. Intern. Med. 171, 1831–1837 (2011).
Cameron, I. D. et al. Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J. Bone Miner. Res. 25, 866–872 (2010).
Ioannidis, G. et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181, 265–271 (2009).
Cauley, J. A., Thompson, D. E., Ensrud, K. C., Scott, J. C. & Black, D. Risk of mortality following clinical fractures. Osteoporos. Int. 11, 556–561 (2000).
Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N. & Eisman, J. A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353, 878–882 (1999).
Jalava, T. et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003).
Kanis, J. A., Oden, A., Johnell, O., De Laet, C. & Jonsson, B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos. Int. 15, 108–112 (2004).
Naves, M. et al. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos. Int. 14, 520–524 (2003).
Bliuc, D. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301, 513–521 (2009).
Morin, S. et al. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos. Int. 22, 2439–2448 (2011).
Cooper, C., Atkinson, E. J., Jacobsen, S. J., O'Fallon, W. M. & Melton, L. J. 3rd. Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137, 1001–1005 (1993).
Browner, W. S., Pressman, A. R., Nevitt, M. C. & Cummings, S. R. Mortality following fractures in older women. The study of osteoporotic fractures. Arch. Intern. Med. 156, 1521–1525 (1996).
Cummings, S. R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761–1767 (2002).
Teng, G. G., Curtis, J. R. & Saag, K. G. Mortality and osteoporotic fractures: is the link causal, and is it modifiable? Clin. Exp. Rheumatol. 26, S125–S137 (2008).
Kanis, J. A. et al. The components of excess mortality after hip fracture. Bone 32, 468–473 (2003).
Lyles, K. W. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357, 1799–1809 (2007).
Center, J. R., Bliuc, D., Nguyen, N. D., Nguyen, T. V. & Eisman, J. A. Osteoporosis medication and reduced mortality risk in elderly women and men. J. Clin. Endocrinol. Metab. 96, 1006–1014 (2011).
Beaupre, L. A. et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos. Int. 22, 983–991 (2011).
Cree, M. W., Juby, A. G. & Carriere, K. C. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos. Int. 14, 722–727 (2003).
Kamel, H. K. Secondary prevention of hip fractures among the hospitalized elderly: are we doing enough? J. Clin. Rheumatol. 11, 68–71 (2005).
Petrella, R. J. & Jones, T. J. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam. Pract. 7, 31 (2006).
Butler, M., Forte, M. L., Joglekar, S. B., Swiontkowski, M. F. & Kane, R. L. Evidence summary: systematic review of surgical treatments for geriatric hip fractures. J. Bone Joint Surg. Am. 93, 1104–1115 (2011).
Della Rocca, G. J. & Crist, B. D. Hip fracture protocols: what have we changed? Orthop. Clin. North Am. 44, 163–182 (2013).
Hu, F., Jiang, C., Shen, J., Tang, P. & Wang, Y. Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. Injury 43, 676–685 (2012).
Miyamoto, R. G., Kaplan, K. M., Levine, B. R., Egol, K. A. & Zuckerman, J. D. Surgical management of hip fractures: an evidence-based review of the literature. I: femoral neck fractures. J. Am. Acad. Orthop. Surg. 16, 596–607 (2008).
Moja, L. G. et al. Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190,000 patients. PLoS ONE 7, e46175 (2012).
Johnell, O. & Kanis, J. A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17, 1726–1733 (2006).
Rapp, K., Becker, C., Lamb, S. E., Icks, A. & Klenk, J. Hip fractures in institutionalized elderly people: incidence rates and excess mortality. J. Bone Miner. Res. 23, 1825–1831 (2008).
Tosteson, A. N., Gottlieb, D. J., Radley, D. C., Fisher, E. S. & Melton, L. J. 3rd. Excess mortality following hip fracture: the role of underlying health status. Osteoporos. Int. 18, 1463–1472 (2007).
Wolinsky, F. D., Fitzgerald, J. F. & Stump, T. E. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am. J. Public Health 87, 398–403 (1997).
Magaziner, J. et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am. J. Public Health 87, 1630–1636 (1997).
Fisher, E. S. et al. Hip fracture incidence and mortality in New England. Epidemiology 2, 116–122 (1991).
Tsuboi, M., Hasegawa, Y., Suzuki, S., Wingstrand, H. & Thorngren, K. G. Mortality and mobility after hip fracture in Japan: a ten-year follow-up. J. Bone Joint Surg. Br. 89, 461–466 (2007).
Vestergaard, P., Rejnmark, L. & Mosekilde, L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos. Int. 18, 1583–1593 (2007).
Haentjens, P. et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann. Intern. Med. 152, 380–390 (2010).
Wehren, L. E. et al. Gender differences in mortality after hip fracture: the role of infection. J. Bone Miner. Res. 18, 2231–2237 (2003).
Chiang, C. H. et al. Hip fracture and risk of acute myocardial infarction: a nationwide study. J. Bone Miner. Res. 28, 404–411 (2013).
Brauer, C. A., Coca-Perraillon, M., Cutler, D. M. & Rosen, A. B. Incidence and mortality of hip fractures in the United States. JAMA 302, 1573–1579 (2009).
Bass, E., French, D. D., Bradham, D. D. & Rubenstein, L. Z. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann. Epidemiol. 17, 514–519 (2007).
Holt, G., Smith, R., Duncan, K., Hutchison, J. D. & Gregori, A. Gender differences in epidemiology and outcome after hip fracture: evidence from the Scottish Hip Fracture Audit. J. Bone Joint Surg. Br. 90, 480–483 (2008).
Mortimore, E. et al. Amount of social contact and hip fracture mortality. J. Am. Geriatr. Soc. 56, 1069–1074 (2008).
Farahmand, B. Y., Michaelsson, K., Ahlbom, A., Ljunghall, S. & Baron, J. A. Survival after hip fracture. Osteoporos. Int. 16, 1583–1590 (2005).
Forsen, L., Sogaard, A. J., Meyer, H. E., Edna, T. & Kopjar, B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos. Int. 10, 73–78 (1999).
Hindmarsh, D. M., Hayen, A., Finch, C. F. & Close, J. C. Relative survival after hospitalisation for hip fracture in older people in New South Wales, Australia. Osteoporos. Int. 20, 221–229 (2009).
Penrod, J. D. et al. The association of race, gender, and comorbidity with mortality and function after hip fracture. J. Gerontol. A Biol. Sci. Med. Sci. 63, 867–872 (2008).
Jacobsen, S. J. et al. Race and sex differences in mortality following fracture of the hip. Am. J. Public Health 82, 1147–1150 (1992).
Hoenig, H., Rubenstein, L. & Kahn, K. Rehabilitation after hip fracture—equal opportunity for all? Arch. Phys. Med. Rehabil. 77, 58–63 (1996).
Harada, N. D., Chun, A., Chiu, V. & Pakalniskis, A. Patterns of rehabilitation utilization after hip fracture in acute hospitals and skilled nursing facilities. Med. Care 38, 1119–1130 (2000).
Paksima, N. et al. Predictors of mortality after hip fracture: a 10-year prospective study. Bull. NYU Hosp. Jt Dis. 66, 111–117 (2008).
Nather, A., Seow, C. S., Iau, P. & Chan, A. Morbidity and mortality for elderly patients with fractured neck of femur treated by hemiarthroplasty. Injury 26, 187–190 (1995).
Schroder, H. M. & Erlandsen, M. Age and sex as determinants of mortality after hip fracture: 3,895 patients followed for 2.5–18.5 years. J. Orthop. Trauma 7, 525–531 (1993).
Poor, G., Atkinson, E. J., O'Fallon, W. M. & Melton, L. J. 3rd. Determinants of reduced survival following hip fractures in men. Clin. Orthop. Relat. Res. 319, 260–265 (1995).
Roche, J. J., Wenn, R. T., Sahota, O. & Moran, C. G. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 331, 1374 (2005).
Hasegawa, Y., Suzuki, S. & Wingstrand, H. Risk of mortality following hip fracture in Japan. J. Orthop. Sci. 12, 113–117 (2007).
Richmond, J., Aharonoff, G. B., Zuckerman, J. D. & Koval, K. J. Mortality risk after hip fracture. 2003. J. Orthop. Trauma 17 (8 Suppl.), S2–S5 (2003).
Jiang, H. X. et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J. Bone Miner. Res. 20, 494–500 (2005).
Pioli, G. et al. Predictors of mortality after hip fracture: results from 1-year follow-up. Aging Clin. Exp. Res. 18, 381–387 (2006).
Pande, I. et al. Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann. Rheum. Dis. 65, 87–92 (2006).
Kannegaard, P. N., van der Mark, S., Eiken, P. & Abrahamsen, B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39, 203–209 (2010).
Fox, K. M., Magaziner, J., Hebel, J. R., Kenzora, J. E. & Kashnei, T. M. Intertrochanteric versus femoral neck hip fractures: differential characteristics, treatment, and sequelae. J. Gerontol. A Biol. Sci. Med. Sci. 54, M635–M640 (1999).
Haentjens, P. et al. Survival and functional outcome according to hip fracture type: a one-year prospective cohort study in elderly women with an intertrochanteric or femoral neck fracture. Bone 41, 958–964 (2007).
Karagiannis, A. et al. Mortality rates of patients with a hip fracture in a southwestern district of Greece: ten-year follow-up with reference to the type of fracture. Calcif. Tissue Int. 78, 72–77 (2006).
Leibson, C. L., Tosteson, A. N., Gabriel, S. E., Ransom, J. E. & Melton, L. J. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J. Am. Geriatr. Soc. 50, 1644–1650 (2002).
Melton, L. J. 3rd. The prevalence of osteoporosis. J. Bone Miner. Res. 12, 1769–1771 (1997).
Cooper, C., Atkinson, E. J., O'Fallon, W. M. & Melton, L. J. 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J. Bone Miner. Res. 7, 221–227 (1992).
Fink, H. A. et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J. Bone Miner. Res. 20, 1216–1222 (2005).
Gehlbach, S. H. et al. Recognition of vertebral fracture in a clinical setting. Osteoporos. Int. 11, 577–582 (2000).
Bouza, C., Lopez, T., Palma, M. & Amate, J. M. Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry. Osteoporos. Int. 18, 649–657 (2007).
Ensrud, K. E. et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J. Am. Geriatr. Soc. 48, 241–249 (2000).
Hasserius, R., Karlsson, M. K., Jonsson, B., Redlund-Johnell, I. & Johnell, O. Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly—a 12- and 22-year follow-up of 257 patients. Calcif. Tissue Int. 76, 235–242 (2005).
Ismail, A. A. et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos. Int. 8, 291–297 (1998).
Lee, A. Y. et al. Five-year outcome of individuals with hip fracture admitted to a Singapore hospital: quality of life and survival rates after treatment. J. Am. Geriatr. Soc. 60, 994–996 (2012).
Lau, E., Ong, K., Kurtz, S., Schmier, J. & Edidin, A. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J. Bone Joint Surg. Am. 90, 1479–1486 (2008).
Pongchaiyakul, C. et al. Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J. Bone Miner. Res. 20, 1349–1355 (2005).
Kado, D. M. et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch. Intern. Med. 159, 1215–1220 (1999).
Lee, Y. K. et al. Mortality after vertebral fracture in Korea: analysis of the National Claim Registry. Osteoporos. Int. 23, 1859–1865 (2012).
Kado, D. M. et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos. Int. 14, 589–594 (2003).
Trone, D. W., Kritz-Silverstein, D., von Muhlen, D. G., Wingard, D. L. & Barrett-Connor, E. Is radiographic vertebral fracture a risk factor for mortality? Am. J. Epidemiol. 166, 1191–1197 (2007).
Melton, L. J. 3rd, Achenbach, S. J., Atkinson, E. J., Therneau, T. M. & Amin, S. Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos. Int. 24, 1689–1696 (2013).
Bolland, M. J., Grey, A. B., Gamble, G. D. & Reid, I. R. Effect of osteoporosis treatment on mortality: a meta-analysis. J. Clin. Endocrinol. Metab. 95, 1174–1181 (2010).
Black, D. M. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348, 1535–1541 (1996).
Cummings, S. R. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280, 2077–2082 (1998).
Harris, S. T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282, 1344–1352 (1999).
Reginster, J. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11, 83–91 (2000).
McClung, M. R. et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344, 333–340 (2001).
Meunier, P. J. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459–468 (2004).
Reginster, J. Y. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90, 2816–2822 (2005).
Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809–1822 (2007).
Nurmi-Luthje, I. et al. Post-fracture prescribed calcium and vitamin D supplements alone or, in females, with concomitant anti-osteoporotic drugs is associated with lower mortality in elderly hip fracture patients: a prospective analysis. Drugs Aging 26, 409–421 (2009).
Sambrook, P. N. et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos. Int. 22, 2551–2556 (2011).
Bondo, L., Eiken, P. & Abrahamsen, B. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos. Int. 24, 245–252 (2013).
Colon-Emeric, C. S. et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J. Bone Miner. Res. 25, 91–97 (2010).
Beloosesky, Y. et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J. Gerontol. A Biol. Sci. Med. Sci. 62, 420–426 (2007).
Miller, R. R. et al. Association between interleukin-6 and lower extremity function after hip fracture—the role of muscle mass and strength. J. Am. Geriatr. Soc. 56, 1050–1056 (2008).
Svensen, C. H. Vascular endothelial growth factor (VEGF) in plasma increases after hip surgery. J. Clin. Anesth. 16, 435–439 (2004).
Onuoha, G. N. & Alpar, E. K. Elevation of plasma CGRP and SP levels in orthopedic patients with fracture neck of femur. Neuropeptides 34, 116–120 (2000).
Roelofs, A. J., Thompson, K., Ebetino, F. H., Rogers, M. J. & Coxon, F. P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des. 16, 2950–2960 (2010).
Hewitt, R. E. et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol. 139, 101–111 (2005).
Farhat, G. N. et al. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study. Calcif. Tissue Int. 79, 102–111 (2006).
Kalinowski, L., Dobrucki, L. W., Brovkovych, V. & Malinski, T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105, 933–938 (2002).
Tuominen, O. M. et al. Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find. Exp. Clin. Pharmacol. 28, 361–367 (2006).
Ugur Ural, A., Avcu, F. & Ozturk, K. Bisphosphonates may retrieve endothelial function in vascular diseases similar to statins' effects. Eur. J. Haematol. 81, 77–78 (2008).
Kang, J. H., Keller, J. J. & Lin, H. C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos. Int. 24, 271–277 (2013).
Shao, W., Orlando, R. C. & Awayda, M. S. Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action. Am. J. Physiol. Cell Physiol. 289, C248–C256 (2005).
Dobrucali, A. et al. Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G576–G586 (2002).
Pittman, C. B. et al. Myocardial infarction risk among patients with fractures receiving bisphosphonates. Mayo Clin. Proc. 89, 43–51 (2014).
Kang, H. Y. et al. Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Public Health 10, 230 (2010).
Muraki, S., Yamamoto, S., Ishibashi, H. & Nakamura, K. Factors associated with mortality following hip fracture in Japan. J. Bone Miner. Metab. 24, 100–104 (2006).
Edidin, A. A., Ong, K. L., Lau, E. & Kurtz, S. M. Mortality risk for operated and nonoperated vertebral fracture patients in the medicare population. J. Bone Miner. Res. 26, 1617–1626 (2011).
K.G.S. receives research support from Amgen and Merck. He also serves as a consultant for Amgen, Eli Lilly and Merck. S.E.S. declares no competing interests.
About this article
Cite this article
Sattui, S., Saag, K. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10, 592–602 (2014). https://doi.org/10.1038/nrendo.2014.125
Association between mortality risk and the number, location, and sequence of subsequent fractures in the elderly
Osteoporosis International (2021)
Combinations of dietary calcium intake and mediterranean-style diet on risk of hip fracture: A longitudinal cohort study of 82,000 women and men
Clinical Nutrition (2021)
Journal of NeuroInterventional Surgery (2020)
Power training improves bone mineral density and fall risk for a postmenopausal woman with a history of osteoporosis and increased risk of falling: A case report
Journal of Bodywork and Movement Therapies (2020)
Bioorganic & Medicinal Chemistry Letters (2020)